Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs

使用组合成熟的 hPSC-CM 对急性和慢性心脏毒性进行预测评估

基本信息

  • 批准号:
    10505634
  • 负责人:
  • 金额:
    $ 12.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-01 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Nearly 90% of drugs under development fail to reach the market. Many of these failures occur due to cardiotoxicity. In a few notable cases, some drugs pass pre-clinical screens and clinical trials, only to be removed from the market once toxic effects are discovered in large patient populations. These failures represent a tremendous source of waste and constitute a significant part of the ~$2 billion cost of bringing a single drug to market. Consequently, the FDA now mandates that all drugs undergo in vitro cardiotoxicity testing before being tested in humans. This has led to a significant and growing market for tools and technologies that enable earlier detection of toxic effects before exposure to patients. However, current screening methods fall short of predicting how a drug will behave in the body; indeed there is a pressing need for more predictive model systems. Further, most screens focus on acute toxicity and do not test for longer-term structural toxicity which is typically only caught after a patient is exposed to the drug over long treatments. Human induced pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) are an attractive model for in vitro preclinical toxicity screening; they are relatively easy to maintain, are derived from human tissue, and have the potential to reduce the need for animal experimentation. However, at present, hPSC-CM based assays do not properly replicate the function of the human heart. These cells exhibit phenotypes similar to that of fetal tissue and do not respond as expected to drugs of known effect; in some cases, known bad-actor drugs fail to induce toxicity in hPSC-CMs, while others only show effects when exposed to supra-physiological doses of the drug in question. The drug discovery industry and its regulators realize the potential of hPSC-CMs for early cardiotoxicity screening, but also understand that—at present—there are significant limitations to their use in the drug development process. Thus, it is clear that the production of mature cardiac tissues that accurately recapitulate in vivo drug responses represents a significant opportunity for reducing cost and waste in drug development. NanoSurface Biomedical, Inc., aims to apply bioengineering approaches to enhance the maturity and predictive power of hPSC-CM cells for highly predictive drug-induced cardiotoxicity screening. We hypothesize that these cells will give more predictive results in in vitro cardiotoxicity detection for both acute and chronic toxicity mechanisms. We will first focus on applying these stimuli and validating their ability to predict toxicity (Phase 1). After this validation, we will characterize the phenotypes of these cells and use them in a variety of assays targeted toward understanding a wide variety of specific toxicity mechanisms that are very difficult to screen in the laboratory (Phase 2). We will use these data to understand the role that cell maturity plays in toxicity detection and create a roadmap for a comprehensive cardiotoxicity screening framework.
项目摘要 近90%的正在开发的药物未能进入市场。这些失败中有许多是由于 心脏毒性。在少数值得注意的情况下,一些药物通过了临床前筛查和临床试验,只能去除 从市场中发现有毒作用的大量患者人群。这些失败代表 浪费的巨大来源,构成了将一种药物带到约20亿美元的重要成本中 市场。因此,FDA现在要求所有药物在进行之前进行体外心脏毒性测试 在人类中测试。这导致了工具和技术的巨大市场,使得能够较早 暴露于患者之前检测有毒作用。但是,当前的筛选方法缺乏预测 药物在体内如何表现;确实,需要更需要更重要的模型系统。更远, 大多数筛查都专注于急性毒性,并且不测试长期结构毒性,通常仅是 患者在长期治疗中暴露于药物后捕获。人类诱导的多能干细胞衍生 心肌细胞(HPSC-CMS)是体外临床前毒性筛查的有吸引力的模型。他们相对 易于维护,源自人体组织,并具有减少动物需求的潜力 实验。但是,目前,基于HPSC-CM的测定不能正确复制该功能 人心。这些细胞表现出与胎儿组织相似的表型,并且没有预期的反应 已知作用的药物;在某些情况下,已知的坏动物药物无法在HPSC-CM中诱导毒性,而其他药物则无法诱导 仅在暴露于相关药物的上生物生理剂量时才显示影响。药物发现 行业及其监管机构意识到HPSC-CMS对早期心脏毒性筛查的潜力,但也 理解,在目前的情况下,它们在药物开发过程中的使用有重大局限性。那, 显然,精确概括体内药物反应的成熟心脏组织的产生 代表了降低药物开发成本和浪费的重要机会。纳米表面生物医学, Inc.,旨在采用生物工程方法来增强HPSC-CM细胞的成熟和预测能力 用于高度预测的药物诱导的心脏毒性筛查。我们假设这些细胞将提供更多 预测性导致急性和慢性毒性机制的体外心脏毒性检测。我们将首先 专注于应用这些刺激并验证其预测毒性的能力(第1阶段)。验证后,我们 将表征这些细胞的表型,并将它们用于针对理解的各种测定法 在实验室中很难筛选的多种特异性毒性机制(第2阶段)。我们将 使用这些数据了解细胞成熟在毒性检测中的作用,并为A创建路线图 全面的心脏毒性筛查框架。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nicholas Andrew Geisse其他文献

Nicholas Andrew Geisse的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nicholas Andrew Geisse', 18)}}的其他基金

High-Throughput NMJ Assay for Botox Potency Screening
用于 Botox 效力筛选的高通量 NMJ 检测
  • 批准号:
    10745380
  • 财政年份:
    2023
  • 资助金额:
    $ 12.31万
  • 项目类别:
A cross-species preclinical platform to enhance the translation of new medicines
加强新​​药转化的跨物种临床前平台
  • 批准号:
    10699196
  • 财政年份:
    2023
  • 资助金额:
    $ 12.31万
  • 项目类别:
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs
使用组合成熟的 hPSC-CM 对急性和慢性心脏毒性进行预测评估
  • 批准号:
    10711373
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs
使用组合成熟的 hPSC-CM 对急性和慢性心脏毒性进行预测评估
  • 批准号:
    10480067
  • 财政年份:
    2020
  • 资助金额:
    $ 12.31万
  • 项目类别:
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs
使用组合成熟的 hPSC-CM 对急性和慢性心脏毒性进行预测评估
  • 批准号:
    10274730
  • 财政年份:
    2020
  • 资助金额:
    $ 12.31万
  • 项目类别:
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs
使用组合成熟的 hPSC-CM 对急性和慢性心脏毒性进行预测评估
  • 批准号:
    10679410
  • 财政年份:
    2020
  • 资助金额:
    $ 12.31万
  • 项目类别:
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs
使用组合成熟的 hPSC-CM 对急性和慢性心脏毒性进行预测评估
  • 批准号:
    9909529
  • 财政年份:
    2020
  • 资助金额:
    $ 12.31万
  • 项目类别:
Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing
生物工程成熟人类多能干细胞来源的心肌细胞用于预测药物引起的毒性测试
  • 批准号:
    10454644
  • 财政年份:
    2019
  • 资助金额:
    $ 12.31万
  • 项目类别:
Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing
生物工程成熟人类多能干细胞来源的心肌细胞用于预测药物引起的毒性测试
  • 批准号:
    10183319
  • 财政年份:
    2019
  • 资助金额:
    $ 12.31万
  • 项目类别:
Multiplexed quantitative measurements of field potential and contractility on biomimetically-matured hPSC-CMs
对仿生成熟 hPSC-CM 的场电位和收缩性进行多重定量测量
  • 批准号:
    9910089
  • 财政年份:
    2019
  • 资助金额:
    $ 12.31万
  • 项目类别:

相似国自然基金

早期环境暴露对儿童哮喘免疫保护的动物实验和机制研究
  • 批准号:
    82300031
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
羊膜间充质干细胞联合水凝胶支架材料移植干预脊髓损伤动物实验研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
深渊片脚类动物原位代谢测量与高质量实验技术研究
  • 批准号:
    42276191
  • 批准年份:
    2022
  • 资助金额:
    54 万元
  • 项目类别:
    面上项目
节肢动物病毒多样性的生态驱动因素研究:以新岗山生态系统功能实验基地为例
  • 批准号:
    32200004
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
羊膜间充质干细胞联合水凝胶支架材料移植干预脊髓损伤动物实验研究
  • 批准号:
    82271408
  • 批准年份:
    2022
  • 资助金额:
    52.00 万元
  • 项目类别:
    面上项目

相似海外基金

Targeting Cholesterol Homeostasis to maintain vision in MS-like optic neuritis
针对多发性硬化症样视神经炎的胆固醇稳态以维持视力
  • 批准号:
    10657163
  • 财政年份:
    2023
  • 资助金额:
    $ 12.31万
  • 项目类别:
Linking Juvenile Experiences with Adult Patterns of Behavior
将青少年经历与成人行为模式联系起来
  • 批准号:
    10620295
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
Linking Juvenile Experiences with Adult Patterns of Behavior
将青少年经历与成人行为模式联系起来
  • 批准号:
    10501980
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs
使用组合成熟的 hPSC-CM 对急性和慢性心脏毒性进行预测评估
  • 批准号:
    10711373
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
Translational Studies of Cannabis Administration, Cognition, and the Endocannabinoid System in HIV
HIV 中大麻施用、认知和内源性大麻素系统的转化研究
  • 批准号:
    10399609
  • 财政年份:
    2021
  • 资助金额:
    $ 12.31万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了